Halaven Study Improves Overall Survival In Liposarcomas and Leiomyosarcomas

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

Full results from a phase III study showed improved median overall survival in unresectable locally advanced liposarcomas and leiomyosarcomas in patients receiving Halaven (eribulin), compared to dacarbazine.

To access this subscriber-only content please log in or subscribe.

If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.

Login Subscribe

YOU MAY BE INTERESTED IN

When Olufunmilayo I. “Funmi” Olopade was born, the most common Nigerian career aspirations were pastor or teacher. Olopade’s father, a pastor, thought differently. He wanted his children to be scientists, economists, and doctors. 

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login